Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of escitalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and a statin, which is a class of lipid-lowering agents. Escitalopram acts primarily by inhibiting the sodium-dependent serotonin transporter (SERT), increasing synaptic serotonin levels to treat major depressive disorder and generalized anxiety disorder[3]. Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing low-density lipoprotein (LDL) cholesterol and overall cardiovascular risk[5]. This combination may be used in patients who require both mood stabilization and lipid management. Evidence suggests that escitalopram can be safely co-administered with most statins without significant pharmacokinetic interactions or increased risk of adverse effects such as myopathy[2]. Some studies suggest that combining SSRIs with statins may have additive or synergistic benefits for depression treatment outcomes[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + statin.